137 related articles for article (PubMed ID: 27856625)
1. Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex.
Häggkvist J; Tóth M; Tari L; Varnäs K; Svedberg M; Forsberg A; Nag S; Dominguez C; Munoz-Sanjuan I; Bard J; Wityak J; Varrone A; Halldin C; Mrzljak L
J Nucl Med; 2017 Apr; 58(4):617-622. PubMed ID: 27856625
[TBL] [Abstract][Full Text] [Related]
2. Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D
Fazio P; Schain M; Mrzljak L; Amini N; Nag S; Al-Tawil N; Fitzer-Attas CJ; Bronzova J; Landwehrmeyer B; Sampaio C; Halldin C; Varrone A
Neuroimage; 2017 May; 152():330-339. PubMed ID: 28254508
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Characterization of mGluR5 Using
Bertoglio D; Kosten L; Verhaeghe J; Thomae D; Wyffels L; Stroobants S; Wityak J; Dominguez C; Mrzljak L; Staelens S
J Nucl Med; 2018 Nov; 59(11):1722-1727. PubMed ID: 29794227
[TBL] [Abstract][Full Text] [Related]
4. Kinetic Modelling and Test-Retest Reproducibility for the Dopamine D
Bertoglio D; Verhaeghe J; Miranda A; Wyffels L; Stroobants S; Dominguez C; Munoz-Sanjuan I; Skinbjerg M; Liu L; Staelens S
Mol Imaging Biol; 2021 Apr; 23(2):208-219. PubMed ID: 33179158
[TBL] [Abstract][Full Text] [Related]
5. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
Ma Q; Yang J; Li T; Milner TA; Hempstead BL
Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
[TBL] [Abstract][Full Text] [Related]
6. [18F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases.
Döbrössy MD; Braun F; Klein S; Garcia J; Langen KJ; Weber WA; Nikkhah G; Meyer PT
Nucl Med Biol; 2012 Oct; 39(7):1077-80. PubMed ID: 22591915
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease.
Peng Q; Wu B; Jiang M; Jin J; Hou Z; Zheng J; Zhang J; Duan W
PLoS One; 2016; 11(2):e0148839. PubMed ID: 26859386
[TBL] [Abstract][Full Text] [Related]
8. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease.
Miller S; Hill Della Puppa G; Reidling J; Marcora E; Thompson LM; Treanor J
J Huntingtons Dis; 2014; 3(4):333-41. PubMed ID: 25575954
[TBL] [Abstract][Full Text] [Related]
9. Relationship between regional gray matter volumes and dopamine D
Kurose S; Kubota M; Takahata K; Yamamoto Y; Fujiwara H; Kimura Y; Ito H; Takeuchi H; Mimura M; Suhara T; Higuchi M
Hum Brain Mapp; 2021 Aug; 42(12):4048-4058. PubMed ID: 34014611
[TBL] [Abstract][Full Text] [Related]
10. Neurochemical correlates of synapse density in a Huntington's disease mouse model.
Zarate N; Gundry K; Yu D; Casby J; Eberly LE; Öz G; Gomez-Pastor R
J Neurochem; 2023 Jan; 164(2):226-241. PubMed ID: 36272099
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride.
Narendran R; Frankle WG; Mason NS; Rabiner EA; Gunn RN; Searle GE; Vora S; Litschge M; Kendro S; Cooper TB; Mathis CA; Laruelle M
Synapse; 2009 Jun; 63(6):447-61. PubMed ID: 19217025
[TBL] [Abstract][Full Text] [Related]
12. Rostrocaudal gradients of dopamine D2/3 receptor binding in striatal subregions measured with [(11)C]raclopride and high-resolution positron emission tomography.
Alakurtti K; Johansson JJ; Tuokkola T; Någren K; Rinne JO
Neuroimage; 2013 Nov; 82():252-9. PubMed ID: 23727314
[TBL] [Abstract][Full Text] [Related]
13. Long-term test-retest reliability of striatal and extrastriatal dopamine D2/3 receptor binding: study with [(11)C]raclopride and high-resolution PET.
Alakurtti K; Johansson JJ; Joutsa J; Laine M; Bäckman L; Nyberg L; Rinne JO
J Cereb Blood Flow Metab; 2015 Jul; 35(7):1199-205. PubMed ID: 25853904
[TBL] [Abstract][Full Text] [Related]
14. Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET.
Rosa-Neto P; Doudet DJ; Cumming P
Neuroimage; 2004 Jul; 22(3):1076-83. PubMed ID: 15219579
[TBL] [Abstract][Full Text] [Related]
15. TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31.
Simmons DA; James ML; Belichenko NP; Semaan S; Condon C; Kuan J; Shuhendler AJ; Miao Z; Chin FT; Longo FM
Hum Mol Genet; 2018 Aug; 27(16):2893-2912. PubMed ID: 29860333
[TBL] [Abstract][Full Text] [Related]
16. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease.
Heikkinen T; Lehtimäki K; Vartiainen N; Puoliväli J; Hendricks SJ; Glaser JR; Bradaia A; Wadel K; Touller C; Kontkanen O; Yrjänheikki JM; Buisson B; Howland D; Beaumont V; Munoz-Sanjuan I; Park LC
PLoS One; 2012; 7(12):e50717. PubMed ID: 23284644
[TBL] [Abstract][Full Text] [Related]
17. Reduced D2/D3 Receptor Binding of Extrastriatal and Striatal Regions in Temporal Lobe Epilepsy.
Bernedo Paredes VE; Buchholz HG; Gartenschläger M; Breimhorst M; Schreckenberger M; Werhahn KJ
PLoS One; 2015; 10(11):e0141098. PubMed ID: 26544593
[TBL] [Abstract][Full Text] [Related]
18. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.
Ooms M; Rietjens R; Rangarajan JR; Vunckx K; Valdeolivas S; Maes F; Himmelreich U; Fernandez-Ruiz J; Bormans G; Van Laere K; Casteels C
Neurobiol Aging; 2014 Dec; 35(12):2858-2869. PubMed ID: 25018107
[TBL] [Abstract][Full Text] [Related]
19. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
20. Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease.
van Oostrom JC; Dekker M; Willemsen AT; de Jong BM; Roos RA; Leenders KL
Eur J Neurol; 2009 Feb; 16(2):226-31. PubMed ID: 19138335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
